Redbiotec and TeselaGen to Partner on Herpesvirus Vaccine Library
Zurich, Switzerland and San Francisco, CA, August 30, 2013 (PRWEB) August 30, 2013 -- Redbiotec will contribute its proprietary rePAX® technology for production of virus-like particles (VLPs) and multi-protein complexes and their expertise in the field of HCMV (human cytomegalovirus) to build a verified library of VLPs/multi-protein complexes for vaccine development and testing. By using TeselaGen’s technology, Redbiotec expects to accelerate the development of the new library. This library also will help reveal potential causes of virus latency and help elucidate virus-triggered cancer mechanisms.
TeselaGen will contribute its proprietary Synthetic Evolution® technology, which uses synthetic biology approaches to build and modify DNA and automate library creation as well as statistical learning approaches to model performance of VLPs/multi-protein complexes and feed information back into the design process. The two companies will work together to enhance their respective technologies to meet the joint venture’s objectives.
“Redbiotec’s deep experience in VLP production and synthetic virology is very valuable to TeselaGen as we develop our technology to solve real world problems. We are very impressed with Redbiotec’s work on HCMV and are eager to help speed the development pipeline to go after vaccine candidates for Herpes,” said Michael Fero, CEO, TeselaGen. “Our partnerships with key industrial sectors in biotechnology are allowing us to build technology that adds a great deal of real-world value. We are convinced our synthetic biology approaches are going to prove very successful.”
“TeselaGen’s experience and capabilities in automated DNA design are very important to Redbiotec”, said Christian Schaub, CEO, Redbiotec. “Our concept for novel Herpesvirus vaccines candidates requires the collection of a large amount of data on DNA as well as on manufacturing and analysis of the expressed viral constructs. In 2012 we surveyed the market for potential partners and discovered an ideal strategic partner in TeselaGen. TeselaGen is at the leading edge in terms of creating bio design technology that talks directly to high-throughput bio-production. After our achievements with HCMV vaccine development we are excited to apply both partners’ skills and technology to extend our pipeline further into Herpesviruses.”
Michael Fero, TeselaGen, http://www.teselagen.com, +1 (650) 387-5932, [email protected]
Share this article